Seer Announces Publication of Seminal Study Demonstrating Superior Performance of Technology Platform for Deep, Unbiased, Precise, Scalable Proteomics in the Proceedings of the National Academy of Sciences
March 14 2022 - 8:00AM
Seer, Inc. (Nasdaq: SEER) today announced
the publication of a study demonstrating the performance
of the technology platform underlying the Proteograph Product
Suite™ for deep, unbiased, precise, scalable proteomics. The paper,
entitled “Engineered Nanoparticles Enable Deep Proteomics Studies
at Scale by Leveraging Tunable Nano-Bio Interactions,” was
published in The Proceedings of the National Academy of
Sciences (PNAS) by an interdisciplinary team of scientists from
Seer, Oregon Health Sciences University, Massachusetts Institute of
Technology, and Harvard Medical School. The study examines in
detail the relationship between the unique physicochemical
properties of a panel of proprietary engineered nanoparticles (NPs)
and the diverse pattern of protein sampling that is enabled by a
unique nano-bio interface that is created between a given NP
surface and a given biological sample. The Seer machine learning
model developed in this paper enhances understanding of the
molecular interactions that occur at the nano-bio interface and
shows how future NPs may be rationally designed using machine
learning to differentially interrogate specific protein families.
The proprietary nanoparticle technology described in
the PNAS paper forms the foundation for Seer’s
Proteograph Product Suite, which is the only at scale solution
available to deliver peptide and amino acid level resolution that
enables identification of proteins and protein variants in an
unbiased manner for deep, precise, and scalable proteomics studies.
Understanding the proteome in health and disease, which is
comprised of millions of protein variants, is believed to be key to
unlocking biological insight to enable precision medicine.
“We are excited about the publication of this seminal paper in
PNAS that further highlights the technological and scientific
underpinning of the Proteograph Product Suite, opening our aperture
to see the vast molecular information embedded in our proteome,”
said Omid Farokhzad, Chief Executive Officer and Chair of Seer. “We
believe that a deeper understanding of the proteome, which can only
be achieved in an unbiased way since the vast majority of the
information is unknown, is key to the next wave of biological
discoveries. These are exciting times for the field, and we’re at a
watershed moment where our access to deep, unbiased proteomics
information at scale is no longer constrained.”
About the Study Findings
Deep, unbiased profiling of the plasma proteome at scale has not
been possible with traditional workflows. In this study, Seer
demonstrates superior performance of the technology platform
underlying the Proteograph Product Suite. The technology platform
simultaneously achieves an order of magnitude gain in median depth
of coverage, 2x higher precision, 2.5x protein identifications and
significant improvement in throughput in comparison to a
conventional deep workflow. The performance of the Proteograph
Product Suite uniquely enables population-scale unbiased studies
where a large number of protein variants may be discovered. This
performance is enabled by a panel of proprietary, engineered
nanoparticles and this study demonstrates that the reproducible and
quantitative dynamic range compression renders peptide and protein
variant information significantly more accessible to downstream
detectors independent of the LC-MS/MS acquisition mode.
Using machine learning, the authors dissected the components of
the physicochemical properties of proprietary engineered
nanoparticles that contribute to the formation and composition of
protein coronas. Correlations were identified between the
physicochemical properties of nanoparticles and the abundance and
functions of the specific proteins that interact with them. This
structure-binding relationship will progressively enhance the
ability to precisely and rationally design proprietary
nanoparticles to orthogonally interrogate protein variants in
different protein families, further enhancing the utility of
nanoparticles in large-scale omics research and biomarker
discovery.
About Seer
Seer is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer’s
Proteograph™ Product Suite is an integrated solution that
includes proprietary engineered nanoparticles, consumables,
automation instrumentation and software to perform deep, unbiased
proteomic analysis at scale in a matter of hours. Seer designed the
Proteograph workflow to be efficient and easy to use, leveraging
widely adopted laboratory instrumentation to provide a
decentralized solution that can be incorporated by nearly any lab.
Seer’s Proteograph Product Suite is for research use only and is
not intended for diagnostic procedures. For more information,
please visit www.seer.bio.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on
Seer’s beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause Seer’s actual results, performance, or
achievements to be materially different from those expressed or
implied by the forward-looking statements. These statements include
but are not limited to statements regarding Seer’s ability to
design proprietary nanoparticles, unlock biological insights, the
ability of the Proteograph to enable unbiased, deep proteomics
studies at scale to deliver new levels of insight, speed, and
sensitivity, to expand unbiased proteomics and the performance of
the technology platform. These and other risks are described more
fully in Seer’s filings with the Securities and Exchange Commission
(“SEC”) and other documents that Seer subsequently files with the
SEC from time to time. Except to the extent required by law, Seer
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Media Inquiries:Karen Possematopr@seer.bio
Investor Inquiries:Carrie
Mendivilinvestor@seer.bio
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024